323 related articles for article (PubMed ID: 35163599)
1. SGLT2 Inhibitors and Their Antiarrhythmic Properties.
Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599
[TBL] [Abstract][Full Text] [Related]
2. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
Xu B; Kang B; Zhou J
Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
[TBL] [Abstract][Full Text] [Related]
3. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
4. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Fernandes GC; Fernandes A; Cardoso R; Penalver J; Knijnik L; Mitrani RD; Myerburg RJ; Goldberger JJ
Heart Rhythm; 2021 Jul; 18(7):1098-1105. PubMed ID: 33757845
[TBL] [Abstract][Full Text] [Related]
5. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
6. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
7. Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund LH; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
Eur J Heart Fail; 2020 Nov; 22(11):1984-1986. PubMed ID: 33068051
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
9. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
Mordi IR; Lang CC
Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibition and heart failure-current concepts.
Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
[TBL] [Abstract][Full Text] [Related]
11. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.
Vrachatis DA; Papathanasiou KA; Iliodromitis KE; Giotaki SG; Kossyvakis C; Raisakis K; Kaoukis A; Lambadiari V; Avramides D; Reimers B; Stefanini GG; Cleman M; Giannopoulos G; Lansky A; Deftereos SG
Drugs; 2021 Aug; 81(12):1381-1395. PubMed ID: 34297330
[TBL] [Abstract][Full Text] [Related]
12. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.
Scheen AJ
Diabetes Metab; 2022 Nov; 48(6):101405. PubMed ID: 36334794
[TBL] [Abstract][Full Text] [Related]
13. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
Herrington WG; Savarese G; Haynes R; Marx N; Mellbin L; Lund LH; Dendale P; Seferovic P; Rosano G; Staplin N; Baigent C; Cosentino F
Eur J Heart Fail; 2021 Aug; 23(8):1260-1275. PubMed ID: 34184823
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
16. The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.
Vardeny O
Am J Med; 2020 Feb; 133(2):182-185. PubMed ID: 31494110
[TBL] [Abstract][Full Text] [Related]
17. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
18. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.
Fawzy AM; Rivera-Caravaca JM; Underhill P; Fauchier L; Lip GYH
Diabetes Obes Metab; 2023 Feb; 25(2):602-610. PubMed ID: 36054168
[TBL] [Abstract][Full Text] [Related]
19. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
20. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes.
Abu-Qaoud MR; Kumar A; Tarun T; Abraham S; Ahmad J; Khadke S; Husami R; Kulbak G; Sahoo S; Januzzi JL; Neilan TG; Baron SJ; Martin D; Nohria A; Reynolds MR; Kosiborod M; Dani SS; Ganatra S
JACC Clin Electrophysiol; 2023 Oct; 9(10):2109-2118. PubMed ID: 37565953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]